Review



plasma sema3a concentrations  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Elabscience Biotechnology plasma sema3a concentrations
    Violin plot comparing plasma <t>Sema3A</t> levels across diagnostic categories. ( A ) Patients vs HCs. ( B ) Acute phase vs subacute phase in RSSI patients. ( C ) Subacute phase vs HCs. ( D ) CI vs NCI subgroup in patients. ( E ) High-load vs low-load CSVD imaging score subgroups. Abbreviations: HC: healthy control; CI: cognitive impairment; NCI: non-cognitive impairment; CSVD: cerebral small vessel disease. *** P < 0.001.ns: not significant.
    Plasma Sema3a Concentrations, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma sema3a concentrations/product/Elabscience Biotechnology
    Average 94 stars, based on 10 article reviews
    plasma sema3a concentrations - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease"

    Article Title: Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease

    Journal: International Journal of General Medicine

    doi: 10.2147/IJGM.S554075

    Violin plot comparing plasma Sema3A levels across diagnostic categories. ( A ) Patients vs HCs. ( B ) Acute phase vs subacute phase in RSSI patients. ( C ) Subacute phase vs HCs. ( D ) CI vs NCI subgroup in patients. ( E ) High-load vs low-load CSVD imaging score subgroups. Abbreviations: HC: healthy control; CI: cognitive impairment; NCI: non-cognitive impairment; CSVD: cerebral small vessel disease. *** P < 0.001.ns: not significant.
    Figure Legend Snippet: Violin plot comparing plasma Sema3A levels across diagnostic categories. ( A ) Patients vs HCs. ( B ) Acute phase vs subacute phase in RSSI patients. ( C ) Subacute phase vs HCs. ( D ) CI vs NCI subgroup in patients. ( E ) High-load vs low-load CSVD imaging score subgroups. Abbreviations: HC: healthy control; CI: cognitive impairment; NCI: non-cognitive impairment; CSVD: cerebral small vessel disease. *** P < 0.001.ns: not significant.

    Techniques Used: Clinical Proteomics, Diagnostic Assay, Imaging, Control

    Correlation analysis of plasma Sema3A levels in the acute phase. ( A ) Correlation between plasma Sema3A levels and MoCA score in RSSI patients. ( B ) Correlation between plasma Sema3A levels and total burden score in RSSI patients.
    Figure Legend Snippet: Correlation analysis of plasma Sema3A levels in the acute phase. ( A ) Correlation between plasma Sema3A levels and MoCA score in RSSI patients. ( B ) Correlation between plasma Sema3A levels and total burden score in RSSI patients.

    Techniques Used: Clinical Proteomics

    ROC analysis of plasma Sema3A levels. ( A ) ROC curve comparing RSSI patients and HCs. ( B ) ROC curve comparing CI and NCI subgroups in RSSI patients.
    Figure Legend Snippet: ROC analysis of plasma Sema3A levels. ( A ) ROC curve comparing RSSI patients and HCs. ( B ) ROC curve comparing CI and NCI subgroups in RSSI patients.

    Techniques Used: Clinical Proteomics

    Mediation analysis of plasma Sema3A, CSVD total burden score, and cognitive function. ( A ) Conceptual diagram of mediation analysis with single mediator (M). Total effect of X on Y (c) = indirect effect through M (a × b) + direct effect (c’). ( B ) Sema3A (X), total burden score (M), MoCA (Y). ( C ) Sema3A (X), LI (M), MoCA (Y). ( D ) Sema3A (X), CMBs (M), MoCA (Y). ( E ) Sema3A (X), EPVs (Potter score) (M), MoCA (Y). ( F ) Sema3A (X), WMH (Fazekas score) (M), MoCA (Y). Covariates: age, sex, education.***P < 0.001.
    Figure Legend Snippet: Mediation analysis of plasma Sema3A, CSVD total burden score, and cognitive function. ( A ) Conceptual diagram of mediation analysis with single mediator (M). Total effect of X on Y (c) = indirect effect through M (a × b) + direct effect (c’). ( B ) Sema3A (X), total burden score (M), MoCA (Y). ( C ) Sema3A (X), LI (M), MoCA (Y). ( D ) Sema3A (X), CMBs (M), MoCA (Y). ( E ) Sema3A (X), EPVs (Potter score) (M), MoCA (Y). ( F ) Sema3A (X), WMH (Fazekas score) (M), MoCA (Y). Covariates: age, sex, education.***P < 0.001.

    Techniques Used: Clinical Proteomics



    Similar Products

    plasma sema3a concentrations  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology plasma sema3a concentrations
    Violin plot comparing plasma <t>Sema3A</t> levels across diagnostic categories. ( A ) Patients vs HCs. ( B ) Acute phase vs subacute phase in RSSI patients. ( C ) Subacute phase vs HCs. ( D ) CI vs NCI subgroup in patients. ( E ) High-load vs low-load CSVD imaging score subgroups. Abbreviations: HC: healthy control; CI: cognitive impairment; NCI: non-cognitive impairment; CSVD: cerebral small vessel disease. *** P < 0.001.ns: not significant.
    Plasma Sema3a Concentrations, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma sema3a concentrations/product/Elabscience Biotechnology
    Average 94 stars, based on 1 article reviews
    plasma sema3a concentrations - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Violin plot comparing plasma Sema3A levels across diagnostic categories. ( A ) Patients vs HCs. ( B ) Acute phase vs subacute phase in RSSI patients. ( C ) Subacute phase vs HCs. ( D ) CI vs NCI subgroup in patients. ( E ) High-load vs low-load CSVD imaging score subgroups. Abbreviations: HC: healthy control; CI: cognitive impairment; NCI: non-cognitive impairment; CSVD: cerebral small vessel disease. *** P < 0.001.ns: not significant.

    Journal: International Journal of General Medicine

    Article Title: Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease

    doi: 10.2147/IJGM.S554075

    Figure Lengend Snippet: Violin plot comparing plasma Sema3A levels across diagnostic categories. ( A ) Patients vs HCs. ( B ) Acute phase vs subacute phase in RSSI patients. ( C ) Subacute phase vs HCs. ( D ) CI vs NCI subgroup in patients. ( E ) High-load vs low-load CSVD imaging score subgroups. Abbreviations: HC: healthy control; CI: cognitive impairment; NCI: non-cognitive impairment; CSVD: cerebral small vessel disease. *** P < 0.001.ns: not significant.

    Article Snippet: Plasma Sema3A concentrations were measured using a double antibody sandwich enzyme-linked immunosorbent assay (ELISA, Human SEMA3A ELISA Kit, Elabscience, Wuhan, China).

    Techniques: Clinical Proteomics, Diagnostic Assay, Imaging, Control

    Correlation analysis of plasma Sema3A levels in the acute phase. ( A ) Correlation between plasma Sema3A levels and MoCA score in RSSI patients. ( B ) Correlation between plasma Sema3A levels and total burden score in RSSI patients.

    Journal: International Journal of General Medicine

    Article Title: Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease

    doi: 10.2147/IJGM.S554075

    Figure Lengend Snippet: Correlation analysis of plasma Sema3A levels in the acute phase. ( A ) Correlation between plasma Sema3A levels and MoCA score in RSSI patients. ( B ) Correlation between plasma Sema3A levels and total burden score in RSSI patients.

    Article Snippet: Plasma Sema3A concentrations were measured using a double antibody sandwich enzyme-linked immunosorbent assay (ELISA, Human SEMA3A ELISA Kit, Elabscience, Wuhan, China).

    Techniques: Clinical Proteomics

    ROC analysis of plasma Sema3A levels. ( A ) ROC curve comparing RSSI patients and HCs. ( B ) ROC curve comparing CI and NCI subgroups in RSSI patients.

    Journal: International Journal of General Medicine

    Article Title: Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease

    doi: 10.2147/IJGM.S554075

    Figure Lengend Snippet: ROC analysis of plasma Sema3A levels. ( A ) ROC curve comparing RSSI patients and HCs. ( B ) ROC curve comparing CI and NCI subgroups in RSSI patients.

    Article Snippet: Plasma Sema3A concentrations were measured using a double antibody sandwich enzyme-linked immunosorbent assay (ELISA, Human SEMA3A ELISA Kit, Elabscience, Wuhan, China).

    Techniques: Clinical Proteomics

    Mediation analysis of plasma Sema3A, CSVD total burden score, and cognitive function. ( A ) Conceptual diagram of mediation analysis with single mediator (M). Total effect of X on Y (c) = indirect effect through M (a × b) + direct effect (c’). ( B ) Sema3A (X), total burden score (M), MoCA (Y). ( C ) Sema3A (X), LI (M), MoCA (Y). ( D ) Sema3A (X), CMBs (M), MoCA (Y). ( E ) Sema3A (X), EPVs (Potter score) (M), MoCA (Y). ( F ) Sema3A (X), WMH (Fazekas score) (M), MoCA (Y). Covariates: age, sex, education.***P < 0.001.

    Journal: International Journal of General Medicine

    Article Title: Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease

    doi: 10.2147/IJGM.S554075

    Figure Lengend Snippet: Mediation analysis of plasma Sema3A, CSVD total burden score, and cognitive function. ( A ) Conceptual diagram of mediation analysis with single mediator (M). Total effect of X on Y (c) = indirect effect through M (a × b) + direct effect (c’). ( B ) Sema3A (X), total burden score (M), MoCA (Y). ( C ) Sema3A (X), LI (M), MoCA (Y). ( D ) Sema3A (X), CMBs (M), MoCA (Y). ( E ) Sema3A (X), EPVs (Potter score) (M), MoCA (Y). ( F ) Sema3A (X), WMH (Fazekas score) (M), MoCA (Y). Covariates: age, sex, education.***P < 0.001.

    Article Snippet: Plasma Sema3A concentrations were measured using a double antibody sandwich enzyme-linked immunosorbent assay (ELISA, Human SEMA3A ELISA Kit, Elabscience, Wuhan, China).

    Techniques: Clinical Proteomics